Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS32581
- Development stage
- Preclinical
- Lead developer
- Akeso
- Modality
- Small Molecules
01
Overview
CS32581 is a preclinical-stage small molecule androgen receptor (AR) antagonist being developed by Chipscreen NewWay, a subsidiary of Shenzhen Chipscreen Biosciences. The drug is designed to target the androgen receptor signaling pathway, which is a critical driver in the development and progression of prostate cancer, including castration-resistant forms. By binding to the AR, CS32581 aims to block the transcriptional activity of androgens, thereby inhibiting tumor growth. It is currently being evaluated in preclinical studies for its potential to treat prostate cancer, with a focus on addressing resistance mechanisms associated with existing AR-targeted therapies.
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on CS32581.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS32581.